GLUE R&D to Revenue
Monte Rosa Therapeutics Inc · R&D to Revenue
GLUE R&D to Revenue
Latest reported534.83%period ending
GLUE Quarterly R&D/Revenue (0.00% → 534.83%)
Latest values, visible window
High-resolution chart · PNG
GLUE r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 534.835% | |
| 1,046.7696% | |
| 1,509.493% | |
| 287.265% | |
| 132.1592% | |
| 37.9022% | |
| 64.0856% | |
| 299.6528% | |
| 553.6741% | |
| 2,361.7481% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% | |
| 0% |